基于类器官的前列腺癌研究进展
Advances in Organoid-Based Prostate Cancer Research

前列腺癌作为男性常见的恶性肿瘤之一，由于其复杂的微环境和显著的肿瘤异质性，使得传统的二维细胞培养技术和动物模型在研究过程中面临诸多挑战。类器官模型作为一种新兴的三维体外培养体系，在癌症研究领域中逐渐成为不可或缺的研究工具。类器官技术能够较好地再现原发组织的结构与功能特性，从而更准确地反映前列腺癌生物学行为如生长、转移及对药物反应等现象。本文综述了该技术在前列腺癌领域的应用进展，重点讨论了它在揭示肿瘤发生机制、促进新药筛选、实现个体化医疗以及探索耐药机制等方面所展现出来的潜力。同时，我们也探讨了当前类器官技术存在的局限性和未来发展方向，包括如何进一步规范和扩大类器官的生产规模、提高模型的一致性等问题。随着这些关键技术难题被逐步解决，预计类器官将在前列腺癌早期诊断、寻找有效治疗靶点及制定更为合理的治疗方案方面发挥更大作用。尽管如此，目前关于类器官标准化大规模培养及其模型稳定性的研究仍存在不少障碍，但若能克服这些问题，并成功将之与“器官芯片”技术相融合，则有望极大提升其在前列腺癌精准医学中的应用价值。
As one of the common malignant tumors in men, prostate cancer faces many challenges in the research process due to its complex microenvironment and significant tumor heterogeneity. As an emerging three-dimensional in vitro culture system, organoid models have gradually become an indispensable research tool in the field of cancer research. Organoid technology can better reproduce the structural and functional properties of the primary tissue, so as to more accurately reflect the biological behavior of prostate cancer, such as growth, metastasis and response to drugs. This article reviews the application progress of this technology in the field of prostate cancer, focusing on its potential in revealing tumorigenesis mechanisms, promoting new drug screening, realizing personalized medicine, and exploring drug resistance mechanisms. At the same time, we also discussed the limitations and future development directions of current organoid technologies, including how to further standardize and expand the production scale of organoids and improve the consistency of models. As these key technical challenges are gradually solved, it is expected that organoids will play a greater role in the early diagnosis of prostate cancer, the search for effective therapeutic targets, and the formulation of more reasonable treatment regimens. However, there are still many obstacles to the current research on standardized large-scale culture of organoids and the stability of their models, but if these problems can be overcome and successfully integrated with “organ-on-a-chip” technology, it is expected to greatly improve its application value in precision medicine for prostate cancer.